Novavax secures deal with New Zealand for 10.7m doses of COVID-19 vaccine
pharmafile | December 17, 2020 | News story | Sales and Marketing | COVID-19, Novavax, Vaccine
Novavax has announced an Advance Purchase Agreement with New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, the biotechnology company’s COVID-19 vaccine candidate.
The jab, a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, is currently in Phase III of clinical testing in the UK. Under the terms of the agreement, Novavax will manufacture the vaccine with a target of delivering the first doses by mid-2021.
The company will work with New Zealand’s regulatory agency Medsafe to obtain product approvals. Given the urgent need for vaccinations during the pandemic, the regulatory review process could leverage review by prioritised regulatory bodies such as the FDA, EMA, and MHRA.
Stanley C Erck, President and Chief Executive Officer of Novavax, said: “The global reach of the pandemic requires that all regions of the world have an adequate supply of vaccine available to protect their entire citizenry.
“We appreciate the confidence of the government of New Zealand and are pleased to contribute to ensuring that New Zealanders will have access to a protein-based vaccine through standard distribution channels, should it receive regulatory approval.”
New Zealand has pre-ordered 15 million COVID-19 vaccine courses from four providers: 750,000 courses from Pfizer, five million from Janssen, 3.8 million from Oxford-AstraZeneca and 5.36 million from Novavax. The vaccine will be free for all New Zealanders, and will be made available in the second quarter of 2021.
Darcy Jimenez
Related Content
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
